# DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

Source: https://onco.cc/trials/nct07707895/  
OnCo record `nct07707895` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of obrixtamig, ZL-1310 and atezolizumab in lung cancer, run by Boehringer Ingelheim, not yet recruiting.

## Summary

DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers is a phase 1/2, interventional study registered as NCT07707895 by Boehringer Ingelheim, with a registry enrolment figure of 60 participants, started 2026-09-29 and due to reach its primary completion in 2030-04-26. Interventions recorded: Obrixtamig; ZL-1310; Atezolizumab. Conditions listed: Small Cell Lung Cancer; Large Cell Neuroendocrine Lung Carcinoma; Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology; Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology. Primary outcome: Part 1: The occurrence of dose limiting toxicities (DLTs) during the DLT evaluation period; Part 2: The occurrence of treatment-emergent adverse events (AEs) leading to trial medication discontinuation or dose modification; Part 2: PFS rate at 6 months. Lung eligibility wording from the registry: "* Small cell lung carcinoma (SCLC)". Sites: Australia, Belgium, China, France, Germany, Japan, Netherlands, Poland, Spain, United Kingdom, United States. United Kingdom sites listed: 2. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07707895
- Phase: 1/2
- Setting: A Phase Ib/II, Open-label, Safety and Tolerability Trial of Obrixtamig in Combination With ZL-1310 in Patients With Poorly Differentiated NEC
- Sponsor: Boehringer Ingelheim
- Enrolled: 60

## Notes

- UK sites (registry): Leicester Royal Infirmary (Leicester); Freeman Hospital (Newcastle upon Tyne).

## Sources

- ClinicalTrials.gov NCT07707895: https://clinicaltrials.gov/study/NCT07707895

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Obrixtamig](https://onco.cc/drugs/obrixtamig/), [ZL-1310](https://onco.cc/drugs/zl-1310/)
- companies: [Boehringer Ingelheim](https://onco.cc/companies/boehringer-ingelheim/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07707895.json